Junshi Biosciences and Coherus Announce Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Clinical Trial Evaluating Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma
February 15, 2023 09:26 ET
|
Junshi Biosciences
- Final overall survival analysis of the JUPITER-02 trial shows first-line treatment with toripalimab plus chemotherapy significantly prolongs survival in patients with advanced NPC - SHANGHAI,...
Junshi Biosciences Announces Approval for Marketing of VV116 in China
January 30, 2023 08:24 ET
|
Junshi Biosciences
SHANGHAI, China, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company...
Junshi Biosciences Announces Acceptance of NDA for VV116 in China
January 17, 2023 23:11 ET
|
Junshi Biosciences
SHANGHAI, China, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company...
Junshi Biosciences Announces Toripalimab as Perioperative Treatment for Operable NSCLC Patients Met Primary Endpoint in Phase 3 Clinical Study
January 17, 2023 22:57 ET
|
Junshi Biosciences
SHANGHAI, China, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company...
Junshi Biosciences Announces NEJM Publication of Results of Phase 3 Study of VV116 Versus PAXLOVID for Adults at High Risk for Progression to Severe COVID-19
December 29, 2022 01:31 ET
|
Junshi Biosciences
SHANGHAI, China, Dec. 29, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company...
Junshi Biosciences and Hikma Sign Exclusive Licensing Agreement for Cancer Treatment Drug Toripalimab for the Middle East and North Africa Region
December 26, 2022 03:06 ET
|
Junshi Biosciences
SHANGHAI, China, Dec. 26, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company...
Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
December 25, 2022 08:16 ET
|
Junshi Biosciences
- FDA has been unable to travel to China to conduct the required site inspection resulting in delayed action on the BLA - - Junshi Biosciences and Coherus are actively engaged in ongoing discussions...
Junshi Biosciences Announces Updated Clinical data from Phase I study of anti-BTLA antibody Tifcemalimab in Treatment of Relapsed/Refractory Lymphomas at 64th ASH Annual Meeting
December 10, 2022 18:30 ET
|
Junshi Biosciences
-- Preliminary study results show that tifcemalimab is well-tolerated at all administered doses. The observed clinical activity of tifcemalimab in combination with toripalimab in lymphoma patients...
Junshi Biosciences Announces Submission of a Marketing Authorization Application for Toripalimab to the UK Medicines and Healthcare Products Regulatory Agency
November 24, 2022 07:30 ET
|
Junshi Biosciences
SHANGHAI, China, Nov. 24, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company...
Junshi Biosciences Announces Approval of Supplemental Application for Additional Indications of Adalimumab Injection
November 22, 2022 01:13 ET
|
Junshi Biosciences
SHANGHAI, China, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company...